“North America accounted for the largest share of the global clinical decision support systems followed by Europe, Asia Pacific, and Rest of the World.”

Clinical Decision Support Systems (CDSS) market in terms of revenue was estimated to be worth $1.7 billion in 2023 and is poised to reach $2.5 billion by 2028, growing at a CAGR of 7.5% from 2023 to 2028 according to a latest report published by MarketsandMarkets™. According to article published in StatPearls 2023, stated that in US 7,000 to 9,000 patients die annually because of medication errors. Integration of CDSS can support the improvement of medication safety and reduce medication-related expenditures and errors. This is possible due to the functionalities of CDSS solutions which includes computerized reminders and advice regarding drug selection, dosage, interactions, allergies, and the scheduling of subsequent orders. Additionally, the growth in this market is majorly driven by the implementation of new government regulations and initiatives to promote the adoption of HCIT solutions. However, high investment necessities for the implementation of clinical decision support systems (CDSS) are are expected to restrain market growth to a certain extent.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=18085342

Clinical Decision Support Systems (CDSS) market major players covered in the report, such as:

• Wolters Kluwer N.V. (Netherlands)
• Oracle (US)
• Merative (US)
• Change Healthcare (US)
• Veradigm Inc. (US)
• athenahealth (US)
• Epic Systems Corporation (US)
• Elsevier B.V. (Netherlands)
• Zynx Health (US)
• Koninklijke Philips N.V. (Netherlands)
• Medical Information Technology, Inc. (US)
• NextGen Healthcare, Inc. (US)
• CureMD Healthcare (US)
• Siemens Healthineers (Germany)
• EBSCO Information Services (US)
• GE HealthCare (US)
• eClinicalWorks (US)
• The Medical Algorithms Company (UK)
• RAMPmedical (Germany)
• Hera-MI (France)
• CareCloud, Inc. (US)
• VisualDx (US)
• Premier, Inc. (US)
• First Databank, Inc. (US)
• Strata Decision Technology (US)
• and Among Others

Buy a Clinical Decision Support Systems (CDSS) Industry Report (232 Pages PDF with Insightful ChartsTables, and Figures): https://www.marketsandmarkets.com/Purchase/purchase_reportNew.asp?id=18085342

The study categorizes the clinical decision support systems market into the following segments and subsegments:By Product

• Integrated CDSS
• Standalone CDSS

By Delivery Mode

• On Premise Mode
• Cloud based Mode

By Model

• Knowledge based CDSS
• Non-Knowledge based CDSS

By Type

• Therapeutic CDSS
• Diagnostic CDSS

By Component

• Services
• Software
• Hardware

By Application

• Advanced CDSS
• Conventional CDSS

By Level of Interactivity Level

• Active CDSS
• Passive CDSS

By Setting

• In Patient
• Ambulatory care settings

By Region

• North America
• US
• Canada
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe (RoE)
• Asia Pacific
• Japan
• China
• India
• Rest of APAC (RoAPAC)
• RoW
• Latin America
• Middle East and Africa

Request for FREE Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=18085342

The key stakeholders in the Clinical Decision Support Systems (CDSS) market include:

• Senior Management
• Supply Chain Manager
• Research & Development Team
• Product Manager/Sales Manager
• Hospitals (public and private)
• Ambulatory surgical centers (ASCs)
• Surgeons, physicians, and operating room staff

Recent Developments:

• In April 2023, Microsoft (US) and Epic Systems Corporation (US) expanded their long-standing strategic collaboration to develop and integrate generative AI into healthcare by combining the scale and power of Azure OpenAI Service with Epic’s industry-leading electronic health record (EHR) software. This co-innovation is focused on delivering a comprehensive array of generative AI- powered solutions integrated with Epic’s EHR to increase productivity, enhance patient care, and improve financial integrity of health systems globally.
• In April 2023, Elsevier B.V. (UK) announced the launch of an upgraded version of its clinical decision support solution, ClinicalKey. This enhanced platform incorporates a comprehensive drug compendium, a cutting-edge mobile application, and seamless integration into Electronic Health Records (EHR). These new features have been strategically designed to offer physicians in the United States and international markets convenient access to reliable and extensive medical content directly at the point of care, speeding up diagnosis and treatment for their patients.
• In February 2023, The province of Nova Scotia, in collaboration with Nova Scotia Health Authority (NSHA) and IWK Health (IWK) entered into a new 10-year agreement has been signed with Oracle (US) to implement an integrated electronic care record across the province for the more than one million Nova Scotians. This technology can help improve the way health professionals use and share patient information.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=18085342

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/clinical-decision-support-systems-market-18085342.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Clinical Decision Support Systems (CDSS) Market is Expected to Reach $2.5 billion | MarketsandMarkets

“Prominent players in the in vitro diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific, Inc (US)”

 In Vitro Diagnostics Market is projected to reach USD 144.7 billion by 2027 from USD 115.8 billion in 2022, at a CAGR of 4.6% according to a new report by MarketsandMarkets™. Growth in the market is driven by changing disease emergence patterns, the growing prevalence of chronic & infectious diseases, and increasing investments from private players. However, an unfavorable reimbursement scenario is expected to restrain the growth of this market during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=703

The instruments segment is expected to reach the highest CAGR during the forecast period

Based on product & service, the IVD market is segmented into reagents & kits, instruments, services, and data management software. The instruments segment is to register the highest growth during the forecast period. The high growth in this market is attributed to the technological advancements in diagnostic analyzers. Market players are focused on innovating and launching IVD analyzers with inbuilt software and technology that aids in faster diagnostic results.

The hematology segment to register the highest growth during the forecast period

Based on technology, the IVD market is segmented into immunoassay/immunochemistry, clinical chemistry, molecular diagnostics, hematology, microbiology, coagulation & hemostasis, urinalysis, and other technologies. The hematology segment is to register the highest CAGR during the forecast period. The growth in this market is attributed to the increasing adoption of point-of-care (POC) testing for hematology diagnostics. Moreover, with the increased demand for hematology testing, market players are introducing innovative point-of-care testing solutions and instruments to aid in faster testing.

The oncology segment to register the highest growth during the forecast period

Based on application the IVD market is segmented into infectious diseases, diabetes, oncology, cardiology, drug testing/pharmacogenomics, HIV/AIDS, autoimmune diseases, nephrology, and other applications. The oncology segment is expected to register the highest CAGR during the forecast period. The increasing government and private funding initiatives for cancer research for early prevention and cure of cancer are expected to increase the adoption of IVD tests for the oncology segment.

The hospital laboratories segment accounted for the largest share of the in vitro diagnostics market

Based on end users, the IVD market is segmented into hospital laboratories, clinical laboratories, academic institutes, POC (point-of-care) testing centers, patients, and other end users. In 2021, hospital laboratories accounted for the largest share of the IVD market. With the rising prevalence of diseases and hospital admissions worldwide, hospital laboratories conduct the maximum number of IVD tests daily. IVD tests help physicians in decision-making and curating accurate treatment plans for their patients.

Asia Pacific region to register the highest CAGR during the forecast period

The high growth rate of this segment can be attributed to the rising healthcare spending by a larger population base, healthcare infrastructure modernization, and the growing penetration of cutting-edge clinical laboratory technologies in the region. Moreover, government efforts to increase awareness about early disease detection, and regular health check-ups to further drive the market growth in the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=703

In Vitro Diagnostics Market Dynamics:

Drivers:

1. Increasing geriatric population and subsequent rise in chronic & infectious diseases
2. Gradual shift from centralized testing to point-of-care testing
3. Growing awareness of early disease diagnosis in emerging economies
4. Emergence of rapid PoC technologies and rising adoption of automated analyzers

Restraints:

1. Unfavorable reimbursement scenario

Opportunities:

1. Introduction of disease-specific biomarkers and tests
2. Growing significance of companion diagnostics
3. Growth opportunities in emerging markets

Challenges:

1. Stringent regulatory & legal guidelines
2. Operational barriers

Key Market Players:

Prominent players in the in vitro diagnostics market include Roche Diagnostics (Switzerland), Danaher Corporation (US), Abbott Laboratories (US), Siemens Healthineers AG (Germany), and Thermo Fisher Scientific, Inc (US). Other players in this market include, Sysmex Corporation (Japan), Becton, Dickinson and Company (BD, US), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMérieux SA (France), Agilent Technologies, Inc. (US), DiaSorin S.p.A (Italy), Illumina, Inc. (US), Hologic, Inc. (US), Devyser (Sweden), PerkinElmer Inc. (US), Chembio Diagnostics, Inc.  (US), SurModics, Inc. (US), Accelerate Diagnostics, Inc. (US), and Merck KGaA (Germany).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=703

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/ivd-in-vitro-diagnostics-market-703.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In Vitro Diagnostics Market 2022 – By Size, Share, Development, Trends Analysis And Global Outlook, 2027

“Siemens is a leading player in the diagnostic imaging market due to its robust imaging product portfolio, including MRI, Ultrasound, X-ray systems, and nuclear imaging equipment. The company has major R&D facilities in Germany, the US, China, and India. The company offers a wide range of products and services in point-of-care diagnostics, laboratory testing, diagnostics and therapeutic screening, and molecular medicine.”

Diagnostic Imaging Market in terms of revenue was estimated to be worth $26.5 billion in 2023 and is poised to reach $34.6 billion by 2028, growing at a CAGR of 5.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include the launch of technologically advanced products by the key players and increasing prevalence of chronic diseases.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=411

Mammography systems segment to register significant growth rate over the forecast period of 2023-2028.

Based on the product, the global diagnostic imaging market is segmented into CT scanners, X-ray imaging systems, ultrasound systems, MRI systems, nuclear imaging systems, and mammography systems. The mammography systems segment is anticipated to register the highest growth rate over the forecast period. The CT scanners segment accounted for the highest share of the diagnostic imaging market in 2022.

Cardiology application segment accounted for the largest share of the CT scanners market, by application in 2022.

Based on application, the diagnostic imaging market is segmented into MRI systems – brain and neurological MRI, spine and musculoskeletal MRI, pelvic and abdominal MRI, vascular MRI, breast MRI, cardiac MRI, ultrasound systems – radiology/general imaging, cardiology, obstetrics/gynecology, vascular applications, urology, other applications, X-ray imaging systems – general radiography, fluoroscopy, dentistry, CT scanners- cardiology, oncology, neurology, and other applications, nuclear imaging systems – cardiology, oncology, neurology, and other applications, and mammography systems. Cardiology application segment accounted for the largest share of the market in 2022 and is also expected to grow at the highest CAGR during the forecast period.

Factors such as the introduction of novel software and rising adoption of high-end instruments in end user facilities drive the growth of the market.

The hospitals segment accounted for the largest share of the diagnostic imaging market, by end user, in 2022

Based on end user, the global diagnostic imaging market is segmented into hospitals, diagnostic imaging centers, and other end users. The hospitals segment accounted for the largest share of the market in 2022. Significant rise in the number of hospitals and rising old-age population are driving the growth of this segment.

The Asia Pacific market to register the highest growth in the market during the forecast period

The Asia Pacific diagnostic imaging market is anticipated to register the highest growth from 2023 to 2028. Major players in the market are focusing on expanding their manufacturing capabilities in the APAC. This region is consistently witnessing a rise in the adoption of high-end equipment. Improvements in healthcare systems and government initiatives for modernizing the healthcare infrastructure are offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=411

Diagnostic Imaging Market Dynamics:

Drivers:

1. Growing geriatric population and subsequent rise in chronic diseases

Restraints:

1. High cost of diagnostic imaging systems

Opportunities:

1.  Growth opportunities in emerging countries

Challenge:

1. Shortage of trained professionals

Key Market Players:

As of 2022, prominent players in the diagnostic imaging market are Siemens Healthineers (Germany), GE Healthcare (US), Koninklijke Philips N.V. (Netherlands), FUJIFILM Corporation (Japan) among others.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=411

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/diagnostic-imaging-market-411.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Diagnostic Imaging Market worth $34.6 billion by 2028

“Browse 186 market data Tables and 49 Figures spread through 233 Pages and in-depth TOC on “Continuous Renal Replacement Therapy Market by Product (Hemofilter, Bloodline, Machines, Dialysates), Modality (SCUF, CVVH, CVVHD, CVVHDF), Age (Adult, Pediatric), Enduser (Hospitals, Ambulatory), and Region – Global Forecast to 2028”

Continuous Renal Replacement Therapy Market in terms of revenue was estimated to be worth $1.4 billion in 2023 and is poised to reach $2.1 billion by 2028, growing at a CAGR of 8.1% from 2023 to 2028 according to a new report by MarketsandMarkets™.

The rise in the global incidence of Acute kidney Injury (AKI) and increase in the demand for effective renal replacement therapy among the patients who are critically ill or in ICU and growing initiatives by the government to increase the awareness about CRRT therapy along with the increase in technologically advancement of the CRRT system are anticipated to fuel the CRRT market growth during the forecast period.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=246917088

“Growing demand for dialysate to support the market growth during the forecast period.”

The significant increase in the demand for CRRT in the treatment of hemodynamically unstable patients attributes to the rising of the CRRT market Moreover, the development and commercialization of novel renal replacement solutions are also some of the factors that support the market growth. Furthermore, many companies are expanding their dialysate product portfolios. For instance For instance, in August 2020, NIPRO CORPORATION acquired shares in dialysate MTN Neubrandenburg GmbH, which is involved in the manufacturing and sales of dialysates. Moreover, there has been an increase in the global incidence of acute kidney injury (AKI), which has driven the demand for dialysates and prompted manufacturers to ramp up dialysate production.

“Asia Pacific likely to emerge as the fastest-growing CRRT market, globally”

The Coninuous renal replacement therapy market is segmented into five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East and Africa.Asia Pacific attributes to the highest growth rate amongst the other regions, The emerging Asian countries, such as China, India, and Japan, are offering significant growth opportunities for market players. The expansion of healthcare infrastructure and increase in disposable incomes, increase incidences of acute kidney disease (AKI), diabetes, hypertension are factors which are likely to support the growth of CRRT market in the region.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=246917088

Continuous Renal Replacement Therapy Market Dynamics:

Drivers:

1. Increase in the prevalence of incidence of acute kidney injury (AKI)

Restraints:

1. High procedural cost of CRRT

Opportunities:

1. Emerging markets in APAC and RoW

Challenge:

1. Shortage of trained ICU professionals in developing nations

Key Market Players of Antibody Drug Conjugates Industry:

The key players in the continuous renal replacement therapy market Fresenius Medical Care AG & Co. KGaA (Germany), Baxter International Inc. (US) and B. Braun Melsungen AG (Germany). These companies adopted strategies such as partnerships, acquisitions, and investments to strengthen their presence in the market

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=246917088

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/continuous-renal-replacement-therapy-market-246917088.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Continuous Renal Replacement Therapy Market worth $2.1 billion by 2028

“North America accounted for the largest share the antimicrobial resistance surveillance market. During forecast period, Asia Pacific to witness high growth rate. America.”

Antimicrobial Resistance Surveillance Market in terms of revenue was estimated to be worth $5.9 billion in 2023 and is poised to reach $7.7 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028 according to a new report by MarketsandMarkets™. Growth in this market is majorly driven by growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies, and growing government initiatives to combat antimicrobial-resistance species.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=21323165

The diagnostic kits segment is expected to account for the largest share of the market during the forecast period

On the basis of solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the increasing demand for rapid and accurate diagnostics for antimicrobial resistance. Diagnostic kits are used to detect the presence of antimicrobial-resistant bacteria in clinical samples, such as blood, urine, and respiratory secretions.

The clinical diagnostics segment is expected to account for the largest share of the market during the forecast period.

On the basis of application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications. In 2023, the clinical diagnostics segment is expected to command the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as need to improve patient outcomes, increasing prevalence of antimicrobial resistance, used to determine the susceptibility of bacteria to different antimicrobial agents.

The hospitals & clinics segment is expected to account for the largest share of the market

On the basis of end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment is expected to command the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the fact that because they are the primary settings where antimicrobial-resistant infections occur and they are required to conduct antimicrobial resistance surveillance.

Asia Pacific to witness the highest growth during the forecast period.

In 2022, North America accounted for the largest share the antimicrobial resistance surveillance market. During forecast period, Asia Pacific to witness high growth rate. America. The Asia Pacific region is expected to offer significant opportunities for the growth of the antimicrobial susceptibility testing market. This is because of the region’s large population and its mix of growing and developed economies, such as Japan, China, and India. In addition, markets in developed countries are becoming increasingly saturated. As a result, manufacturers and suppliers are shifting their focus to Asia Pacific.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=21323165

Antimicrobial Resistance Surveillance Market Dynamics:

Drivers:1.  Growing prevalence of infections caused by drug-resistance pathogens

Restraints:1.  High cost of antimicrobial resistance diagnostic systems/ kits

Opportunities:1.  Growth opportunities in emerging economies

Challenge:1.  Complex Regulatory Frameworks

Key Market Players:

The prominent players in this market are Biomerieux (France), Lumed (US), Liofilchem S.r.l. (Italy), BioSpace (US), Bruker (US), Bio-Rad (US), Abbott Laboratories (US), Qiagen (Germany), Cepheid (US), Accelerate Diagnostics, Inc. (US), Roche Diagnostics (Switzerland),  Luminex Corporation (US), Merck KgaA (Germany), Thermo Fisher Scientific (US), Danaher (US), Becton, Dickinson and Company (US), OpGen, Inc. (US), Alifax S.r.l. (Italy), Wolters Kluwer N.V. (US), and Bioanalyse (Turkey).

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=21323165

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/antimicrobial-resistance-surveillance-market-21323165.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Antimicrobial Resistance Surveillance Market worth $7.7 billion | MarketsandMarkets